Research Summary

Dr. Carnevale is a physician-scientist who treats patients with gastrointestinal cancers, and also performs research into finding novel therapies for these diseases.

Research Funding

  • September 1, 2020 - August 31, 2025 - Using CRISPR engineering to develop more potent T cell therapies that are resistant to suppression in the tumor microenvironment , Principle Investigator . Sponsor: Burroughs Wellcome Fund, Sponsor Award ID: 1020881
  • July 15, 2020 - June 30, 2025 - Targeting SOCS1 and RASA2 to Engineer More Potent Adoptive T Cell Therapies for Cancer Treatment. , Principal Investigator . Sponsor: NIH, Sponsor Award ID: K08CA252605

Education

06/2017 - Oncology - ABIM Research Pathway, UCSF
06/2013 - Internal Medicine Residency, UCSF
M.D., 05/2011 - Cancer Biology, Harvard Medical School
B.A., 05/2005 - Human Biology, Stanford University

Selected Publications

  1. Liu T, Zhang M, Farsh T, Li H, Kishishita A, Barpanda A, Leung SG, Zhu J, Jung H, Hua JT, Zhu X, Kim AB, Goo YA, Son M, Kim J, Subramanian A, Sjöström M, Fuh KC, Chapman JS, Carnevale J, Gilbert LA, Lakkaraju A, Bruno PM, Quigley D, Wiita AP, Feng FY, DeSelm CJ. Exploitable mechanisms of antibody and CAR mediated macrophage cytotoxicity. Nat Commun. 2025 Jul 01; 16(1):5616.  View on PubMed
  2. Epstein L, Weiner AC, Verma A, Saedi M, Carnevale J, Marson A, Engelhardt BE Live-cell analyses with unsegmented images to study cancer cell response to modified T cell therapy.  View on PubMed
  3. Maya M Arce, Jennifer Umhoefer, Nadia Arang, Sivakanthan Kasinathan, Jacob W Freimer, Zachary Steinhart, Haolin Shen, Mineto Ota, Anika Wadhera, Minh T.N Pham, Rama Dajani, Dmytro Dorovsky, Yan Yi Chen, Qi Liu, Brian R Shy, Julia Carnevale, Ansuman T Satpathy, Nevan J Krogan, Jonathan K Pritchard, Alexander Marson. Abstract PR008: CD4+ T cell rest and activation is enabled by centralized control of state specific regulatory genes. Cancer Immunology Research. 2025 Feb 23; 13(2_Supplement):pr008-pr008.  View on PubMed
  4. Blennemann M, Verma A, Bachl S, Carnevale J, Engelhardt BE. Understanding TCR T cell knockout behavior using interpretable machine learning. Pac Symp Biocomput. 2025; 30:382-393.  View on PubMed
  5. Arce MM, Umhoefer JM, Arang N, Kasinathan S, Freimer JW, Steinhart Z, Shen H, Pham MTN, Ota M, Wadhera A, Dajani R, Dorovskyi D, Chen YY, Liu Q, Zhou Y, Swaney DL, Obernier K, Shy BR, Carnevale J, Satpathy AT, Krogan NJ, Pritchard JK, Marson A. Central control of dynamic gene circuits governs T cell rest and activation. Nature. 2025 Jan; 637(8047):930-939.  View on PubMed
  6. Verma A, Yu C, Bachl S, Lopez I, Schwartz M, Moen E, Kale N, Ching C, Miller G, Dougherty T, Pao E, Graf W, Ward C, Jena S, Marson A, Carnevale J, Van Valen D, Engelhardt BE. Cellular behavior analysis from live-cell imaging of TCR T cell-cancer cell interactions. bioRxiv. 2024 Nov 21.  View on PubMed
  7. Gregory P. Botta, Ronan Joseph Kelly, Zhaohui Jin, Hong Ma, Geoffrey Yuyat Ku, Dan Zhao, Rutika Mehta, Julia C. Carnevale, Gloria Sierra, Jie JIA, Raffaele Baffa, Zhonghai Li, Dae Won Kim, Harry H. Yoon. CLDN18.2 chimeric antigen receptor T cell therapy for patients with advanced gastric and pancreatic adenocarcinoma: Results of ELIMYN18.2 phase 1b clinical trial. Journal of Clinical Oncology. 2024 Jan 20; 42(3_suppl):356-356.  View on PubMed
  8. Stefanie Bachl, Alexis Talbot, Carter Ching, Nupura Kale, Zhongmei Li, Morgan Diolaiti, Amy Peixin Chen, Joseph Muldoon, Chang Liu, Thomas Martin, Justin Eyquem, Julia Carnevale. Ablation of Cullin-5 in Primary Human T Cells Improves Tumor Killing and Persistence in BCMA-Targeting CAR-T Cells in a Multiple Myeloma Model. Blood. 2023 Nov 28; 142(Supplement 1):99.  View on PubMed
  9. Blaeschke F, Chen YY, Apathy R, Daniel B, Chen AY, Chen PA, Sandor K, Zhang W, Li Z, Mowery CT, Yamamoto TN, Nyberg WA, To A, Yu R, Bueno R, Kim MC, Schmidt R, Goodman DB, Feuchtinger T, Eyquem J, Jimmie Ye C, Carnevale J, Satpathy AT, Shifrut E, Roth TL, Marson A. Modular pooled discovery of synthetic knockin sequences to program durable cell therapies. Cell. 2023 09 14; 186(19):4216-4234.e33.  View on PubMed
  10. N. Fidelman, C. Atreya, M. Griffith, A. Milloy, J. Carnevale, A. Venook, K. Van Loon. Abstract No. 266 Phase I Prospective Trial of TAS-102 (Trifluridine and Tipiracil) and Radioembolization with 90Y Resin Microspheres for Chemo-Refractory Colorectal Liver Metastases. Journal of Vascular and Interventional Radiology. 2023 Mar 1; 34(3):s120.  View on PubMed
  11. Fidelman N, Atreya CE, Griffith M, Milloy MA, Carnevale J, Cinar P, Venook AP, Van Loon K. Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with 90Y resin microspheres for chemo-refractory colorectal liver metastases. BMC Cancer. 2022 Dec 13; 22(1):1307.  View on PubMed
  12. O'Leary PC, Chen H, Doruk YU, Williamson T, Polacco B, McNeal AS, Shenoy T, Kale N, Carnevale J, Stevenson E, Quigley DA, Chou J, Feng FY, Swaney DL, Krogan NJ, Kim M, Diolaiti ME, Ashworth A. Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2. Cancer Res. 2022 11 02; 82(21):3950-3961.  View on PubMed
  13. Carnevale J, Shifrut E, Kale N, Nyberg WA, Blaeschke F, Chen YY, Li Z, Bapat SP, Diolaiti ME, O'Leary P, Vedova S, Belk J, Daniel B, Roth TL, Bachl S, Anido AA, Prinzing B, Ibañez-Vega J, Lange S, Haydar D, Luetke-Eversloh M, Born-Bony M, Hegde B, Kogan S, Feuchtinger T, Okada H, Satpathy AT, Shannon K, Gottschalk S, Eyquem J, Krenciute G, Ashworth A, Marson A. RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature. 2022 09; 609(7925):174-182.  View on PubMed
  14. Belk JA, Yao W, Ly N, Freitas KA, Chen YT, Shi Q, Valencia AM, Shifrut E, Kale N, Yost KE, Duffy CV, Daniel B, Hwee MA, Miao Z, Ashworth A, Mackall CL, Marson A, Carnevale J, Vardhana SA, Satpathy AT. Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence. Cancer Cell. 2022 07 11; 40(7):768-786.e7.  View on PubMed
  15. Andrea Grace Bocobo, Renee Wang, Spencer Behr, Julia C. Carnevale, Pelin Cinar, Eric Andrew Collisson, Lawrence Fong, Bridget P Keenan, Wesley Allen Kidder, Andrew H. Ko, Kanti Pallav Kolli, Megan Kennedy, Angela Laffan, Sorbarikor Piawah, Marin Pollak, Gabriel Schwartz, Julia Whitman, Li Zhang, Katherine Van Loon, Chloe Evelyn Atreya. Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 2022 Jun 1; 40(16_suppl):3565-3565.  View on PubMed
  16. Walker EJ, Blanco AM, Carnevale J, Cinar P, Collisson EA, Tempero MA, Ko AH. The Additional Diagnostic Benefit of Pancreatic Cancer Molecular Profiling After Germline Testing. Pancreas. 2022 04 01; 51(4):302-304.  View on PubMed
  17. Byrnes JR, Weeks AM, Shifrut E, Carnevale J, Kirkemo L, Ashworth A, Marson A, Wells JA. Hypoxia Is a Dominant Remodeler of the Effector T Cell Surface Proteome Relative to Activation and Regulatory T Cell Suppression. Mol Cell Proteomics. 2022 04; 21(4):100217.  View on PubMed
  18. Walker EJ, Goldberg D, Gordon KM, Pedley C, Carnevale J, Cinar P, Collisson EA, Tempero MA, Ko AH, Blanco AM, Dhawan M. Implementation of an Embedded In-Clinic Genetic Testing Station to Optimize Germline Testing for Patients with Pancreatic Adenocarcinoma. Oncologist. 2021 11; 26(11):e1982-e1991.  View on PubMed
  19. R. Aggarwal, S. Umetsu, M. Dhawan, J. Grabowsky, J. Carnevale, M. Howell, L. Wilch, J. Chapman, E. Alvarez, S. Calabrese, S. Smith, N. Shah, E. Dean, P. Munster, E. Collisson. 512O Interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumor malignancies. Annals of Oncology. 2021 Sep 1; 32:s583.  View on PubMed
  20. Tsang ES, Walker EJ, Carnevale J, Fisher GA, Ko AH. Durable response after immune checkpoint inhibitor-related diabetes in mismatch repair-deficient pancreatic cancer. Immunotherapy. 2021 10; 13(15):1249-1254.  View on PubMed

Go to UCSF Profiles, powered by CTSI